

NHS Grampian Formulary Group Decisions for SMC advice published April to June 2023



This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April to June 2023.

For the latest Formulary Group decisions see the [Grampian Area Formulary website](#).

June 2023

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](#)

NHS Grampian Formulary Group Decisions for SMC advice published April to June 2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
darolutamide 300mg film-coated tablets (Nubeqa®)	2544	Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.	Not routinely available as not recommended for use in NHS Scotland, SMC 2544 https://www.scottishmedicines.org.uk/media/7507/darolutamide-nubeqa-final-march-2023-amended-20032023-for-website.pdf	18/04/2023
empagliflozin 10mg film-coated tablet (Jardiance®)	2523	In adults for the treatment of symptomatic chronic heart failure with preserved ejection fraction (left ventricular ejection fraction [LVEF] >40%).	Decision deferred to future meeting, Updates decision 16/05/23	20/06/2023
icosapent ethyl 998mg soft capsules (Vazkepa®)	2531	To reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥ 1.7 mmol/L) and - established cardiovascular disease, or - diabetes, and at least one other cardiovascular risk factor	Not routinely available as not recommended for use in NHS Scotland, SMC 2531 https://www.scottishmedicines.org.uk/media/7564/icosapent-ethyl-vazkepa-final-april-2023-for-website.pdf	16/05/2023
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	2519	In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) with tumour cell programmed death ligand 1 (PD-L1) expression $\geq 1\%$.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/06/2023
patiromer sorbitex calcium 8.4g, 16.8g powder for oral suspension (Veltassa®)	2568	Treatment of hyperkalaemia in adults. SMC restriction: in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2526	As monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma and who have undergone complete resection.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023

NHS Grampian Formulary Group Decisions for SMC advice published April to June 2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
pembrolizumab 25mg/mL concentrate for solution for infusion (Keytruda®)	2538	In combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of adults with locally advanced, or early stage triple-negative breast cancer (TNBC) at high risk of recurrence.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/06/2023
polatuzumab vedotin 30mg, 140mg powder for concentrate for solution with infusion (Polivy®)	2525	In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL). SMC restriction: patients with an International Prognostic Index (IPI) score of 2 to 5.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/06/2023
rimegepant 75mg oral lyophilisate (Vydura®)	2521	For the acute treatment of migraine with or without aura in adults. SMC restriction: for patients who have had inadequate symptom relief after trials of at least two triptans or in whom triptans are contraindicated or not tolerated; and have inadequate pain relief with non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol.	Routinely available in line with local guidance, Updates decision 16/05/23	20/06/2023
rimegepant 75mg oral lyophilisate (Vydura®)	2567	For the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.	Not routinely available as not recommended for use in NHS Scotland, SMC 2567 https://www.scottishmedicines.org.uk/media/7567/rimegepant-vydura-preventative-final-april-2023-for-website.pdf	16/05/2023

NHS Grampian Formulary Group Decisions for SMC advice published April to June 2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
tafasitamab 200mg powder for concentrate for solution for infusion (Minjuvi®)	2522	In combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).	Not routinely available as not recommended for use in NHS Scotland, SMC 2522 https://www.scottishmedicines.org.uk/media/7566/tafasitamab-minjuvi-final-april-2023-for-website.pdf	16/05/2023
tixagevimab 150mg/mL plus cilgavimab 150mg/mL solution for injection (Evusheld®)	2580	Pre-exposure prophylaxis of COVID-19 in adults who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and: - who are unlikely to mount an adequate immune response to COVID-19 vaccination or - for whom COVID-19 vaccination is not recommended	Not routinely available as not recommended for use in NHS Scotland, NICE TA900 https://www.nice.org.uk/guidance/TA900	20/06/2023
trastuzumab deruxtecan 100mg powder for concentrate for solution for infusion (Enhertu®)	2545	As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. SMC restriction: in patients who have received one prior anti-HER2-based regimen.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/04/2023
treosulfan 1g, 5g powder for solution for infusion (Trecondi®)	2527	In combination with fludarabine as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases. SMC restriction: in patients with malignant disease for whom a reduced intensity conditioning regimen is required.	Routinely available from a specialist centre in another health board	20/06/2023

NHS Grampian Formulary Group Decisions for SMC advice published April to June 2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
upadacitinib 15mg, 30mg, 45mg prolonged release tablets (Rinvoq®)	2575	For the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, or for whom such therapies are not advisable.	Routinely available in line with national guidance, SMC 2575 https://www.scottishmedicines.org.uk/media/7611/upadacitinib-rinvoq-abbreviated-final-may-2023-for-website.pdf	20/06/2023